Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Bohn

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Radiation Oncology (London, England)|October 25, 2018
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancerSébastien Thureau, Bernard Dubray, Romain Modzelewski, et al.
Cancers|March 29, 2023
Quantitative MRI to Characterize Hypoxic Tumors in Comparison to FMISO PET/CT for Radiotherapy in Oropharynx CancersPierrick Gouel, Françoise Callonnec, Franchel-Raïs Obongo-Anga, et al.
ACS Chemical Neuroscience|February 20, 2015
Dihydroquinoline Carbamate Derivatives as "Bio-oxidizable" Prodrugs for Brain Delivery of Acetylcholinesterase Inhibitors: [¹¹C] Radiosynthesis and Biological EvaluationPierre Bohn, Fabienne Gourand, Cyril Papamicaël, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 15, 2019
Radiotherapy boost in patients with hypoxic lesions identified by <sup>18</sup>F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2010
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical studyNicolas Aide, Mélanie Briand, Pierre Bohn, et al.
Biomolecules|March 25, 2020
Development of Novel <sup>111</sup>-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid TumoursBenjamin Poret, Laurence Desrues, Marc-André Bonin, et al.
Cancers|August 27, 2021
First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung CancerSébastien Thureau, Nicolas Piton, Pierrick Gouel, et al.
Frontiers in Cell and Developmental Biology|May 3, 2021
Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in GlioblastomaVadim Le Joncour, Pierre-Olivier Guichet, Kleouforo-Paul Dembélé, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2017
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by <sup>18</sup>F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study)Pierre Vera, Sébastien Thureau, Philippe Chaumet-Riffaud, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Radiation Oncology (London, England)|October 25, 2018
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancerSébastien Thureau, Bernard Dubray, Romain Modzelewski, et al.
Cancers|March 29, 2023
Quantitative MRI to Characterize Hypoxic Tumors in Comparison to FMISO PET/CT for Radiotherapy in Oropharynx CancersPierrick Gouel, Françoise Callonnec, Franchel-Raïs Obongo-Anga, et al.
ACS Chemical Neuroscience|February 20, 2015
Dihydroquinoline Carbamate Derivatives as "Bio-oxidizable" Prodrugs for Brain Delivery of Acetylcholinesterase Inhibitors: [¹¹C] Radiosynthesis and Biological EvaluationPierre Bohn, Fabienne Gourand, Cyril Papamicaël, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 15, 2019
Radiotherapy boost in patients with hypoxic lesions identified by <sup>18</sup>F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2010
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical studyNicolas Aide, Mélanie Briand, Pierre Bohn, et al.
Biomolecules|March 25, 2020
Development of Novel <sup>111</sup>-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid TumoursBenjamin Poret, Laurence Desrues, Marc-André Bonin, et al.
Cancers|August 27, 2021
First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung CancerSébastien Thureau, Nicolas Piton, Pierrick Gouel, et al.
Frontiers in Cell and Developmental Biology|May 3, 2021
Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in GlioblastomaVadim Le Joncour, Pierre-Olivier Guichet, Kleouforo-Paul Dembélé, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2017
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by <sup>18</sup>F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study)Pierre Vera, Sébastien Thureau, Philippe Chaumet-Riffaud, et al.
Pageof 4